FindTrial
Sign In

Thoracic Lymphadenopathy in LDCT Lung Cancer Screening: Clinical Significance and Management Strategies

Thoracic Lymphadenopathy in LDCT Lung Cancer Screening: Clinical Significance and Management Strategies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122625
Enrollment
Unknown
Registered
2026-04-15
Start date
2026-04-16
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The etiologies of thoracic lymphadenopathy detected through LDCT lung cancer screening include sarcoidosis, tuberculosis, malignant lymph node metastasis, among others

Interventions

Observational Group (thoracic lymphadenopathy/ non-thoracic lymphadenopathy):None
Group of thoracic lymphadenopathy:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Participants receiving LDCT for lung cancer screening from Jan 2010 to Dec 2025 at West China Hospital, Sichuan University; 2. >=18 years old; 3. Consecutive five-year follow-up with CT.

Exclusion criteria

Exclusion criteria: 1. Inability to cooperate in completing the examination; 2. Lack of baseline or follow-up data.

Design outcomes

Primary

MeasureTime frame
CT images;Diagnosis of thoracic disease;Demographic charateristics;Clinicopathological characteristics;Laboratory examinations;—

Secondary

MeasureTime frame
All-cause mortality;—

Countries

China

Contacts

Public ContactWang Kaige

West China Hospital of Sichuan University

532951643@qq.com+86 15928981470

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026